The agreement spans three areas of distribution: products marketed under the ProBiotix CholBiome^® brand, YourBiotix private turnkey solutions to be sold to South Korea based brand owners and sales of product solutions under TopHealth’s own consumer brand.

TopHealth develops health supplements with a particular focus in the area of probiotics.

It has a portfolio of products for digestive, immune, women’s and children’s health, including several dosage formats ranging from instant melt sticks to capsules, tablets and drops.

Last year, the probiotics dietary supplements market in South Korea was estimated to be worth £350m and is expected to increase to £870m by 2030.

Steen Andersen, CEO of ProBiotix, said: “We are pleased to have managed to secure a market leader like Tophealth.

“It is a company with a proven track record of building strong businesses in the probiotic sector, and today ranks as one of the leading brand innovators in the South Korean supplement market.

“South Korea poses a perfect fit for our value proposition being a high price growth market, with an increasing focus by consumers on probiotic supplements to help manage their health.

“TopHealth has worked diligently with the influencer market, harnessing their large followings to influence consumer purchasing decisions. We expect this increasing awareness to drive demand for our products in the years ahead.”

Tae Yoon Kim, founder & CEO of TopHealth, added: “This partnership with ProBiotix represents a significant opportunity for TopHealth, as we both share a common vision of improving consumer health through scientifically validated solutions.

“By combining innovative science from ProBiotix with TopHealth‘s deep market expertise, we aim to further strengthen our leadership in the Korean probiotics market.“

For more information and the source, visit: Life sciences company secures long-term distribution deal in South Korea | TheBusinessDesk.com